Andere Sprachen NLS Pharmaceutics Ltd.

Aktien

A2P21Z

CH0523961370

NLSP

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 17.05.2024			% 5 Tage	% 1. Jan.
0,164 ^USD	+9,77 %		+17,73 %	-72,20 %

08.04.	Nls Pharmaceutics Ltd. gibt Rücktritt von Anthony S. Walsh als Mitglied des Board of Directors bekannt	CI
23.02.	NLS Pharmaceutics legt Plan zur Wiedererlangung der Nasdaq-Zulassung vor	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

NLS Pharmaceutics : SECOND ADDENDUM TO THE - Form 6-K	14.05.
Nls Pharmaceutics Ltd. Announces Resignation of Anthony S. Walsh as A Member of the Board of Directors	08.04.
NLS Pharmaceutics Ltd. announced that it has received $1.75 million in funding	03.04.
NLS Pharmaceutics : Various Claims Against the Company - Form 6-K	20.03.
NLS Pharmaceutics : SECOND ADDENDUM TO THE - Form 6-K	20.03.
NLS Pharmaceutics Ltd. announced that it expects to receive $1.75 million in funding	20.03.
NLS Pharmaceutics to Participate in the BIO-EUROPE Springtime Partnering Event	15.03.
NLS Pharmaceutics Submits Plan to Regain Listing Compliance with Nasdaq	26.02.
NLS Pharmaceutics Files Plan to Regain Nasdaq Listing Compliance	23.02.
NLS Pharmaceutics - Notice of Deficiency with Nasdaq Continued Listing Requirements	15.01.
Press release titled: “NLS Pharmaceutics CEO Issues Letter to Shareholders.” - Form 6-K	29.12.
NLS Pharmaceutics : Ordinary Shareholders’ Meeting Results - Form 6-K	22.12.
NLS Pharmaceutics : UNAUDITED INTERIM CONDENSED FINANCIAL STATEMENTS - Form 6-K	06.12.
NLS Pharmaceutics AG Reports Earnings Results for the Half Year Ended June 30, 2023	06.12.
Sector Update: Health Care Stocks Rise in Late Afternoon Trading	01.12.
Sector Update: Health Care Stocks Rise in Afternoon Trading	01.12.
Top Midday Gainers	01.12.
NLS Pharmaceutics Signs Option Agreement to Acquire Rights to Aexon Labs' Assets; Shares Rise	01.12.
NLS Pharmaceutics Announces Election of Additional Board Members	29.11.
NLS Pharmaceutics to Participate in the Oppenheimer Sleep Disorders Summit, Deep Dive into Narcolepsy and Idiopathic Hypersomnia	28.11.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen NLS Pharmaceutics Ltd.

Aktien

A2P21Z

CH0523961370

NLSP

Andere Sprachen

Filter